Background: Resistant hypertension is a common clinical problem that both primary care clinicians and specialists encounter worldwide. The 7ili joint national national committee (JNC 7) defined resistant hypertension as inability to achieve a blood pressure lower than 140/90 mm Hg despite optimal doses of 3 or more antihypertensive drugs, including 1 diuretic.
Methods: Literarture search was done through PubMed and Cochrane using the search terms spironolactone, resistant hypertension, and randomized controlled trial. This study included 4 randomized controlled trials.
Results: There was a total number of 439 patients in the spironolactone group and 430 participants in the placebo group. In the spironolactone group there was a statistically significant reduction in systolic blood pressure compared to the placebo group at the end of treatment period, with a mean difference of -13.75 (-18.96, -8.53), p<O.OOOOl.The same observation was seen comparing the diastolic blood pressure between the spironolactone and placebo groups, where the mean difference was -5.71 (-9.36, -2.07), p<O.002, in favor of spironolactone.
Conclusion: Spironolactone as an add-on therapy drug for resistant hypertension effectively red es ) both systolic and diastolic blood pressure.